Tuesday was a relatively uneventful news day for Pfizer, especially following the pharmaceutical giant's disclosure on Monday that it halted the development of its investigational weight loss drug ...

The researcher behind the downgrade was top U.S. lender Bank of America, in the person of pundit Bryan Spillane. He changed his view of PepsiCo from buy to neutral, and cut his price target to $155 ...

In another blow to its prestige, LVMH's stock price swoon knocked the company from its perch as the most valuable luxury ...

After rising roughly 14% in Monday's trading, Newsmax stock is continuing to move higher in today's session. The stock is seeing some significant recovery after big sell-offs last week, but the gains ...

While Apple is getting a big break, the relief may be short lived. President Trump later clarified that electronics like Apple's iPhones would be moving into a different tariff "bucket." While Apple's ...

Quantum computing could be the next frontier for computers and cloud-based services. While traditional computers still store data in binary bits of zeros and ones, quantum compute ...

With a solid balance sheet and $96 billion in cash, Alphabet is well-equipped to navigate any macroeconomic environment.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer. The Motley Fool reaches millions of people every month through our premium ...

The goal is to buy well-located assets when their price falls to attractive levels, increase their value through development and redevelopment, and then willingly sell them for the right price.

In coverage published this morning, Cantor Fitzgerald raised its rating on Verve Therapeutics stock from neutral to overweight -- indicating that the firm thinks the stock is a good buy. The firm's ...